-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...
More »SEARCH RESULT
Total Matching Records found : 2827
Costly Ethanol import likely to make petrol pricier by 4 rupees-Rajeev Jayaswal
-The Economic Times NEW DELHI: Petrol could become costlier by about 4 a litre if the government compels oil firms to sell 5% ethanol-blended petrol across the country by next month as these companies would be forced to import huge quantities of the biofuel at exorbitant rates. But, the Cabinet, which will meet soon to discuss the issue, may relax compulsory doping as it would want petrol prices to rise sharply, months...
More »40% of Mumbai suicides due to family issues, illnesses second -V Narayan
-The Times of India Four out of every 10 suicides in Mumbai from 2007 to 2011 were due to family problems, according to data from the National Crime Records Bureau (NCRB). Similarly, 36% of suicides across the state during the same period were due to family problems. The trend was nationwide, with domestic issues being the main cause of suicides in high-incidence cities like Bangalore, Chennai and Delhi, and states like...
More »USFDA scrutiny: Will pharma majors like Ranbaxy, Wockhardt be affected in long-term? -G Seetharaman
-The Economic Times Japanese companies do not mind erring on the side of caution. They are known to think longer and harder than their counterparts in other countries about big decisions, especially when it comes to entering a new market or acquiring a foreign company. But Japan's third biggest drugmaker Daiichi Sankyo would now wish it had spent more time doing due diligence on Ranbaxy Labs, in which it bought a...
More »Ranbaxy case may take a toll on other Indian drug makers
-The Business Standard The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals. Last week, Ranbaxy had agreed to...
More »
